BridgeBio Pharma, Inc. Employee Count
The employee counts BridgeBio Pharma, Inc. states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 834; Filing 2026-02-24; Lease expense per employee $11,613.91.
- 2024-12-31: Employees (as filed) 725; Filing 2025-02-20; Lease expense per employee $14,910.34.
- 2023-12-31: Employees (as filed) 550; Filing 2024-02-22; Lease expense per employee $20,538.18.
- 2022-12-31: Employees (as filed) 392; Filing 2023-02-23; Lease expense per employee $29,992.35.
- Available history
- 2019-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 834 full-time | 2026-02-24 | $11,613.91 total lease cost |
| 2024-12-31 | 725 full-time | 2025-02-20 | $14,910.34 total lease cost |
| 2023-12-31 | 550 full-time | 2024-02-22 | $20,538.18 total lease cost |
| 2022-12-31 | 392 full-time | 2023-02-23 | $29,992.35 total lease cost |
| 2021-12-31 | 578 | 2022-02-25 | $17,743.94 total lease cost |
| 2020-12-31 | 113 | 2021-02-25 | $40,946.90 total lease cost |
| 2019-12-31 | 248 full-time | 2020-03-03 | $11,290.32 lease and rental expense |
Headcount breakdown as filed
| Fiscal year end | Employees | Xbrl:PlanName | Xbrl:ConsolidatedEntities | Filing |
|---|---|---|---|---|
| 2023-12-31 | 550 full-time | TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlan: 88 | EidosTherapeuticsInc: 88 | 2024-02-22 “As of December 31, 2023, we had 550 full-time employees and six part-time employees. Of these, 388 focus on driving forward research and development programs and 38 focus on our commercialization efforts, either directly or through our affiliates, and 130 work across our affiliates to provide strategic business development, finance and executive leadership expertise, as well as general and…” |
| 2022-12-31 | 392 full-time | TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlan: 88 | EidosTherapeuticsInc: 88 | 2023-02-23 “As of December 31, 2022, we had 392 full-time employees and four part-time employees. Of these, 297 focus on driving forward research and development programs, either directly or through our affiliates, and 99 work across our affiliates to provide strategic business development, finance and executive leadership expertise, as well as general and administrative services generally across our affiliates.” |
| 2021-12-31 | 578 | TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlan: 88 | EidosTherapeuticsInc: 88 | 2022-02-25 “As of December 31, 2021, we had 578 employees, 566 of whom are employed by our wholly-owned subsidiary, BridgeBio Services, Inc., upon which we rely for various administrative, research and development and other support services shared among us.” |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |